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Abstract  Conservative  therapies,  such  as  active  surveillance,  can  be  appropriate  treatment  for
low-risk  prostate  cancer.  The  aim  of  this  study  was  to  analyze  the  frequency  of  Gleason  score
(GS) upgrading  in  patients  with  a  low-grade  GS.  We  reviewed  our  prospectively  maintained
database  of  patients  with  prostate  cancer  that  underwent  radical  prostatectomy  within  the
time frame  of  2004--2015.  Potential  predictors  of  upgrading  in  patients  with  GS  3  +  3  were
studied. Of  the  342  patients  in  our  database,  125  had  GS  3  +  3.  Biopsy  GS  and  surgical  GS  were
identical  in  71  (56.8%)  patients  with  GS  3  +  3,  whereas  54  (43.2%)  patients  had  an  upgrade.
The GS  was  upgraded  to  7  in  70%  of  those  patients  and  to  ≥8  in  30%.  We  found  a  statistically
signiﬁcant  correlation  between  postoperative  upgrade  and  the  preoperative  prostate-speciﬁc
antigen  density  (PSAD)  value  (p  <  0.001),  prostate  volume  (p  =  0.004),  and  patient  age  ≥70  years
(p =  0.011).  We  estimated  an  optimal  PSAD  cutoff  point  of  0.17  ng/ml2 through  ROC  analysis,
with an  AUC  of  0.675  (p  =  0.001).  It  is  our  opinion  that  every  hospital  center  offering  active
surveillance  should  carry  out  a  continuous  review  of  upgrading  and  related  risk  factors.
© 2016  Published  by  Masson  Doyma  Me´xico  S.A.  on  behalf  of  Sociedad  Mexicana  de  Urolog´ıa.
This is  an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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Resumen  El  cáncer  de  próstata  de  bajo  riesgo  es  susceptible  de  ser  tratado  con  terapias
conservadoras  como  la  vigilancia  activa.  El  objetivo  de  este  estudio  es  analizar  la  frecuencia
del incremento  de  la  escala  de  Gleason  (GS)  en  pacientes  con  puntuaciones  de  bajo  grado.
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sometidos  a  prostatectomía  radical  entre  2004  y  2015.  Se  investigaron  los  posibles  predictores
de incremento  postoperatorio  de  GS  en  los  pacientes  con  3  +  3.  El  GS  obtenido  en  la  biopsia  y
en la  pieza  quirúrgica  fue  idéntico  en  71  pacientes  (56.8%),  mientras  que  54  pacientes  (43.2%)
tuvieron  un  incremento  de  la  escala.  De  los  cuales,  el  70%  cambiaron  a  un  GS  de  7  mientras
que el  30%  a  un  GS  ≥8.  Se  encontró  una  correlación  estadísticamente  signiﬁcativa  entre  el
incremento  de  GS  postoperatorio  y  el  PSAD  (p  <0.001),  el  volumen  prostático  (p  =  0.004)  y  la
edad ≥  70  an˜os  (p  =  0.011).  Estimamos  un  punto  de  corte  óptimo  de  PSAD  mediante  análisis  ROC
de 0.17  ng/ml2 con  una  AUC  de  0.675  (p  =  0.001).  Consideramos  que  una  revisión  permanente
del incremento  de  GS  y  los  factores  de  riesgo  relacionados  debe  hacerse  en  cada  institución
que ofrece  vigilancia  activa.
© 2016  Publicado  por  Masson  Doyma  Me´xico  S.A.  en  nombre  de  Sociedad  Mexicana  de  Urolog´ıa.
Este es  un  art´ıculo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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with  an  automatic  biopsy  gun  to  obtain  the  prostatic  tissue.ntroduction
rostate  cancer  is  the  most  common  form  of  malignancy
nd  the  second  leading  cause  of  cancer  death  among  men.1
adaveric  studies  show  that  the  possibility  of  developing
rostate  cancer  micro-foci  increases  with  age  (30%  in  the
ourth  decade  of  life,  40%  in  the  ﬁfth  decade,  etc.).2
While  some  cancers  are  aggressive,  others  have  lit-
le  or  no  metastatic  potential.3 Many  men  with  low-risk
rostate  cancer  will  not  progress  or  become  clinically  symp-
omatic  within  their  lifespan.4 Because  of  this  variability,
ifferent  treatment  options  have  been  introduced,  offer-
ng  comparable  therapeutic  effects  to  radical  prostatectomy
RP),  while  preserving  sexual  function  and  continence.  In
his  scenario,  active  surveillance  (AS)  may  offer  reduced
orbidity  and  improvement  in  quality  of  life.5 Small,  non-
ggressive  tumors  are  the  ideal  candidates  for  AS,  albeit
o  consensus  has  been  reached.  Low-risk  disease  is  deﬁned
s  Gleason  score  (GS)  6  and  prostate-speciﬁc  antigen  (PSA)
10  ng/ml.  Patients  with  clinical  stage  >T2a  are  usually
xcluded.6
Histologic  grade  is  an  independent  determinant  of  dis-
ase  prognosis  and  survival.7 The  GS  grading  system  is  the
ost  widely  accepted  classiﬁcation,8 but  many  studies  have
hown  that  the  GS  obtained  from  prostate  biopsy  does  not
lways  correlate  with  the  ﬁnal  pathologic  grade  of  the  sur-
ical  specimens.  GS  upgrade  (increase  in  GS  of  at  least
ne  point)  has  been  reported  in  up  to  57%  of  cases.9,10
rrors  in  the  assignment  of  GS  may  lead  to  the  inappropri-
te  surveillance  of  biologically  aggressive  tumors,  or  to  the
election  of  treatments  with  inferior  curing  rates  in  high-risk
isease,  which  may  ultimately  have  a  negative  impact  on
atient  outcomes.11 Therefore,  several  recent  studies  have
earched  for  factors  that  could  predict  GS  upgrading.12
Low  prostate  volume  (PV),  and  more  speciﬁcally,  high
rostate-speciﬁc  antigen  density  (PSAD)  have  been  shown
o  be  predictors  of  risk  progression  in  many  studies,  reﬂect-
ng  the  possibility  of  undetected  aggressive  cancer.6 Several
tudies  have  shown  a  strong  relationship  between  PSAD
nd  prostate  cancer  aggressiveness.13 PSAD  has  been  pro-
osed  as  a  strong  predictor  of  GS  upgrade  in  patients  with
iopsy-conﬁrmed  Gleason  6  disease,  but  there  is  no  general
onsensus  on  the  cut-off  value.11--17
F
o
nThe  main  aim  of  our  study  was  to  identify  the  inde-
endent  predictors  for  GS  upgrade  and  determine  the  best
ut-off  value  for  PSAD  to  identify  at-risk  patients.
aterials and methods
e  collected  the  study  information  from  our  hospital
enter’s  prospectively  maintained  database.  Patients  with
linically  localized  prostate  cancer  that  underwent  radical
rostatectomy  (RP)  and  had  a  preoperative  prostate  biopsy
ithin  the  time  frame  of  January  2004  to  February  2015  were
elected.  The  detection  of  GS  3  +  3  at  prostate  biopsy  was
aken  as  inclusion  criteria.  All  clinical,  imaging,  laboratory,
nd  pathologic  information  was  obtained  from  the  database
nd  corroborated  by  the  clinical  case  records  of  the  patients.
We  included  preoperative  patient  age,  clinical  disease
tage,  pre-biopsy  PSA,  preoperative  PSAD,  biopsy  GS,  total
umber  of  biopsy  cores  taken,  and  number  of  biopsy  cores
ith  cancer  and  analyzed  the  association  of  these  factors
ith  GS  upgrading  after  RP.  Different  cut-off  values  were
sed  for  each  variable  to  identify  and  quantify  a  potential
elationship  with  Gleason  upgrade.  We  also  analyzed  the
ssociation  of  GS  upgrade  with  metabolic  syndrome  varia-
les,  such  as  diabetes  mellitus  (DM),  high  blood  pressure
HBP),  and  obesity,  which  were  obtained  from  the  patients’
linical  records.  The  last  variables  were  included  because
revious  studies  have  shown  their  association  with  worse
rognosis  and  a  higher  recurrence  rate.18,19
PSAD  was  calculated  by  dividing  the  preoperative  PSA
alue  by  the  PV.  PV  was  calculated  by  transrectal  ultrasound
sing  the  maximum  transverse  diameter  (D1),  the  maximum
nteroposterior  diameter  (D2),  and  the  maximum  longitu-
inal  diameter  (D3),  using  the  formula  D1  ×  D2  ×  D3  ×  /6
ased  on  the  prostate  ellipse  dimension  theory.14 Prostate
iopsy  was  performed  using  our  hospital’s  previously
escribed  protocol.  All  patients  were  mildly  sedated  and  a
ingle  i.v.  dose  of  piperacillin/tazobactam  was  administered
5  min  before  the  procedure.20 We  used  an  18-gauge  needleor  the  ﬁrst  biopsy,  12--18  cores  were  retrieved,  depending
n  the  size  of  the  prostate  and  the  presence  of  suspicious
odules.21 All  samples  were  placed  in  a  separate  container
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that  identiﬁed  the  corresponding  site  and  were  sent  to  the
pathology  service  of  our  hospital.
Descriptive  statistics  were  presented  as  mean  ±  standard
deviation  (SD)  and  median/IQR  for  continuous  variables  and
as  the  absolute  frequency  and  distribution  percentage  for
categorical  variables.  Patients  postoperatively  upgraded  to
GS  7  or  higher  were  compared  with  those  that  were  not
upgraded.  To  determine  mean  differences  and  similarities,
the  categorical  variables  were  compared  using  the  Pear-
son  chi-square  test  and  the  continuous  variables  with  the
median  test  and  Student’s  t test.  A  univariate  regression
test  was  used  for  detecting  signiﬁcant  independent  predic-
tors  of  upgrading.  A  receiver  operating  characteristic  (ROC)
curve  was  used  and  the  area  under  the  curve  (AUC)  was  cal-
culated  to  show  the  optimal  cut-off  value  for  variables  with
predictive  signiﬁcance  for  GS  upgrade.  We  estimated  the
sensitivity,  speciﬁcity,  positive  predictive  value,  and  neg-
ative  predictive  value  of  different  cut-off  points  proposed
i
t
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Table  1  Characteristics  of  patients  with  and  without  upgrade  of  
Characteristics  Upgrade  
No.  of  patients  (%)  54  (43.2%)  
Age (years)
Mean  ±  SD  66.22  ±  6.5  
Age  (no.)
>70  years  of  age  20  
<70  years  of  age  34  
BMI (kg/m2)
Mean  ±  SD 26.22  ±  4.0
PSA  (ng/ml)
Median/IQR  8/6.5--12.6  
Prostate  volume  (ml)
Median/IQR  30.6/22.5--43.5  
PSAD  (ng/ml2)
Mean  ±  SD  .36  ±  .27  
Biopsy  cores  (no.)
Mean  ±  SD  12.9  ±  3.4  
Positive  cores  (no.)
Mean  ±  SD  2.9  ±  2.4  
Obesity  (no.)
Positive  9  (16.6%)  
Negative  45  (83.4%)  
DM (no.)
Positive  16  (29.6%)  
Negative  38  (70.4%)  
HBP (no.)
Positive  21  (38.9%)  
Negative  33  (61.1%)  
IQR: interquartile range; BMI: body mass index; PSA: prostate-speciﬁc
mellitus; HBP: high blood pressure.
a X2 test.
b Student’s t-test.
c Median test.
* Statistically signiﬁcant with a p value <0.05.341
y  other  authors,  applied  them  to  our  population,  and  then
ompared  them  with  our  cut-off  value.  All  tests  were  two-
ailed  and  a  p  value  of  <0.05  was  considered  statistically
igniﬁcant.  The  analyses  were  performed  using  SPSS  version
0  (SPSS  Inc,  Chicago,  IL)  software.
esults
rom  a  total  of  342  patients  in  our  database,  144  (42.1%)
ere  excluded  because  they  had  a  GS  ≥4  in  the  prostate
iopsy.  This  left  198  (57.9%)  patients  that  met  our  inclusion
riteria  of  GS  6  (3  +  3).  Seventy-three  of  those  patients  were
xcluded  due  to  incomplete  clinical  information  from  the
edical  records.
Mean  patient  age  was  65.1  ±  6.3  years,  body  mass
ndex  (BMI)  was  26.7  ±  3.6  kg/m2, the  number  of  cores
aken  was  13.4  ±  3.5,  the  number  of  positive  cores  was
.5  ±  2,  and  preoperative  PSAD  was  0.26  ±  0.23  ng/ml2.  The
Gleason  score  after  radical  prostatectomy.
No  upgrade  p-Value
71  (56.8%)
64.28  ±  6.0  0.092b
12  0.011*,a
59
27.14  ±  3.1  0.178c
6.8/5.4--9  0.039*,c
46/32.2--63.7  0.007*,c
.19  ±  .16  <0.001*,c
13.7  ±  3.7  0.240c
2.1  ±  1.6  0.0702c
16  (22.5%)  0.500a
55  (77.5%)
14  (19.7%)  0.150a
57  (80.3%)
30  (42.2%)  0.775a
41  (57.8%)
 antigen; PSAD: prostate-speciﬁc antigen density; DM: diabetes
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Table  2  Analysis  of  different  cutoff  values  of  PSAD  as  a  predictor  of  GS  upgrade.
Upgrade  No  upgrade  p  Odds  ratio  Sens  %  Spec  %  PPV  %  NPV  %
PSAD  (no.)
≥0.13  44  (81.5%)  42  (59.2%)  0.008*a 3.03  81.5  40.8  51.1  74.3
<0.13 10  (18.5%)  29  (40.8%)
PSAD  (no.)
≥0.15  43  (79.6%)  35  (49.3%)  0.001*a 4.02  79.6  50.7  55.1  76.5
<0.15 11  (20.4%)  36  (50.7%)
PSAD  (no.)
≥0.17*  41  (75.9%)  29  (40.8%)  <0.001*a 4.56  75.9  59.2  58.5  76.3
<0.17* 13  (24.1%) 42  (59.2%)
PSAD  (no.)
≥0.23  36  (66.6%)  22  (31%)  <0.001*a 4.4  66.7  69  62  73.1
<0.23 18  (33.4%)  49  (69%)
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Table  3  Independent  predictors  of  upgrading  (univariate
regression).
Characteristics  HR  95  CI  p  value
Age  0.5  0.99--1.11  0.09
>70 years  of  age  1.06  1.26--6.63  0.039*
BMI 0.072  0.97--1.18  0.166
PSAD ≥0.13  1.11  1.32--6.99  0.009*
PSAD ≥0.15  1.39  1.79--9.03  0.001*
PSAD ≥0.17  1.51  2.98--9.99  <0.001*
PSAD ≥0.23  1.49  2.08--9.49  <0.001*
PSA 0.05  0.99--1.11  0.059
Prostate  volume  0.02  1.01--1.04  0.008*
Positive  biopsy  cores  0.06  0.98--1.18  0.24
Obesity  0.31  0.54--3.40  0.507
DM 0.61  0.79--4.27  0.152
HBP 0.10  0.53--2.29  0.775
BMI: body mass index; PSA: prostate-speciﬁc antigen; PSAD:
p
A
y
i
b
≥
s
u
o
7
f
pPSAD: prostate-speciﬁc antigen.
a X2 test.
reoperative  median  PSA  was  7.2  IQR  5.67--10.05  and  PV
as  38  IQR  26.5--55.5.  Clinical  stage  based  on  digital  rec-
al  examination  was  T1c  in  86  (69.6%)  patients,  T2a  in  28
22.4%),  T2b  in  7  (5.6%),  T2c  in  2  (1.6%),  and  T3  in  one  (0.8%)
atient.
Preoperative  PSA  was  categorized  as  follows:  6  (4.8%)
atients  had  PSA  values  <4  ng/ml,  88  (70.4%)  were  between  4
nd  9.9  ng/ml,  23  (18.4%)  were  between  10  and  19.9  ng/ml,
nd  8  (6.4%)  had  PSA  ≥20  ng/ml.  The  biopsy  GS  and  sur-
ical  GS  remained  the  same  in  71  (56.8%)  patients  with
S  3  +  3,  whereas  54  (43.2%)  patients  had  an  upgrade.  Of
hose  patients  with  upgrade,  70%  rose  to  a  GS  of  7  and  30%
ncreased  to  ≥8.
Table  1  shows  the  demographic  and  clinical  character-
stics  of  patients  with  and  without  GS  upgrade.  We  found
 statistically  signiﬁcant  correlation  between  postoperative
pgrade  and  the  preoperative  PSAD  value  (p  <  0.001),  preop-
rative  PSA  (p  =  0.039),  PV  (p  =  0.004),  and  patient  age  ≥70
ears  (p  =  0.011).
We  estimated  an  optimal  PSAD  cut-off  point  of
.17  ng/ml2 through  ROC  analysis,  with  an  AUC  of  0.675
p  = 0.001,  95%CI  .580--.770),  and  then  analyzed  the  cut-
ff  values  proposed  by  other  authors  and  compared  them.
able  2  and  Fig.  1  show  those  results.
Table  3  shows  the  results  from  the  univariate  regression
or  the  detection  of  independent  predictors  of  upgrading.
iscussion
everal  studies  have  found  a  lack  of  concordance  between
he  GS  report  from  the  prostate  biopsy  and  the  radical
rostatectomy  report.  In  a  recent  meta-analysis  including
4,839  patients,  the  authors  estimated  a  GS  upgrade  in  30%
f  the  patients,  with  only  63%  remaining  unchanged  after
rostatectomy.22 Gleason  upgrade  has  been  found  in  29--58%
f  cases,23 and  is  worse  in  the  sub-group  of  patients  with  a
iopsy  GS  3  +  3  (up  to  63.3%).14 In  our  hospital  center,  we
ound  a  GS  upgrade  in  42.1%  of  all  patients  that  underwent
adical  prostatectomy  and  in  43.2%  of  the  patients  with  a
iopsy  Gleason  score  of  3  +  3.
t
v
a
wprostate-speciﬁc antigen density; DM: diabetes mellitus; HBP:
high blood pressure.
Many  authors  have  tried  to  ﬁnd  predictors  of  GS  upgrade,
articularly  with  the  currently  increasing  popularity  of  the
S  protocols.  Previously  described  predictors  are  age  >60
ears,  PSA  value  >5.0  ng/ml,  and  >25%  of  positive  cores  dur-
ng  biopsy.24
PSAD  has  been  analyzed  and  several  cut-off  values  have
een  described  (such  as  ≥0.13  ng/ml,  ≥0.15  ng/ml,  and
0.23  ng/ml).11,13,16,17 Nevertheless,  there  is  no  consen-
us  on  the  use  of  this  value  to  accurately  predict  a  GS
pgrade.  Based  on  our  results,  we  proposed  a  cut-off  value
f  ≥0.17  ng/ml,  which  had  an  AUC  of  0.675,  sensitivity  of
5.9%,  speciﬁcity  of  59.2%,  PPV  of  58.5%,  and  NPV  of  76.3%
or  the  prediction  of  GS  upgrade.  We  selected  this  cut-off
oint,  because  when  analyzing  other  proposed  values  in  rela-
ion  to  our  case  series,  the  best  AUC  was  obtained  with  a
alue  ≥0.23  ng/ml  (0.678),  but  it  had  a  worse  sensitivity
nd  a  high  false  negative  rate  (33.33%).  On  the  other  hand,
hen  we  used  the  ≥0.13  ng/ml  and  ≥0.15  ng/ml  values,  they
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Figure  1  ROC  curve.
Figure  2  The  study  population,  showing  the  different  prostate-speciﬁc  antigen  densities  and  upgrade  data.
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R44  
ad  a  false  positive  rate  of  59%  and  49%,  respectively.  The
alse  negative  rate  and  false  positive  rate  of  the  cut-off  pro-
osed  by  our  team  was  24%  and  41%,  respectively,  which  we
onsidered  the  most  useful.  Fig.  2  displays  a  graph  of  our
opulation.
Our  study  included  only  patients  with  a  biopsy  GS  of  3  +  3,
ecause  of  the  importance  of  this  variable  when  consider-
ng  a  patient  for  AS.  Given  that  there  are  other  factors  taken
nto  consideration  for  active  surveillance,  we  cannot  declare
hat  the  risk  of  GS  upgrade  and  PSAD  are  determining  varia-
les  for  proposing  a  therapeutic  strategy,  but  we  deﬁnitely
elieve  they  should  be  discussed  before  making  a  decision.
 second  biopsy  could  be  indicated  for  patients  with  a  PSAD
0.17  ng/ml,  considering  the  risk  of  under-classiﬁcation,  in
rder  to  corroborate  the  GS.  Prostate  MRI  and  MRI-guided
usion  biopsies  have  shown  high  sensitivity  and  speciﬁcity
or  locating  unidentiﬁed  signiﬁcant  cancer.25 However,  these
ptions  are  not  widely  available  in  Mexico,  so  transrectal
ltrasound-guided  saturation  or  template  biopsy  could  be  a
ore  viable  option  to  increase  diagnostic  accuracy.
Recent  evidence  has  suggested  an  association  between
he  different  components  of  metabolic  syndrome  and
rostate  cancer,  increasing  the  risk  of  presenting  with  the
isease  and  dying  from  it,21 as  well  as  a  higher  rate  of  bio-
hemical  recurrence  after  radical  treatment.22 However,  in
ur  study  we  could  not  demonstrate  an  association  with
leason  score  upgrade.
Prostate  volume,  which  is  directly  related  to  age,  could
e  a  distracting  element.  When  a  random  ultrasound-guided
iopsy  is  carried  out  in  a  large  prostate  there  is  a  potential
isk  of  leaving  larger  under-sampled  areas,  which  represents
 higher  risk  of  missing  a  signiﬁcant  tumor.
AS  has  provided  promising  results  in  patients  with  low-
isk  prostate  cancer,  with  improvements  in  quality  of
ife,  preservation  of  erectile  function  and  urinary  conti-
ence,  and  in  other  complications  associated  with  radical
reatments.6 However,  there  is  a  risk  of  misdiagnosing
n  aggressive  cancer  and  delaying  opportune  treatment,
ffecting  patient  prognosis.  There  are  many  criteria  for
electing  AS  candidates,  and  the  D’Amico  risk  classiﬁcation26
nd  Epstein  criteria27 are  the  most  widely  used  for  this  pur-
ose.  The  former  does  not  include  PSAD,  but  in  the  Epstein
riteria  the  use  of  a  cut-off  value  ≥0.15  ng/ml  is  suggested.
n  our  hospital,  we  use  very  strict  criteria  and  the  PSAD
ut-off  value  ≥0.17  ng/ml  will  be  included  as  part  of  the
iscussion  when  selecting  a  possible  candidate  for  AS.
The  retrospective  character  of  our  study  was  its  principal
imitation.  The  potential  sample  was  reduced  even  further
ue  to  incomplete  data  in  the  clinical  case  records.  Another
imitation  was  the  fact  that  we  did  not  have  all  the  data  from
he  biopsy  samples,  so  we  could  not  analyze  patients  with
he  full  AS  criteria.  However,  with  the  amount  of  patients
ncluded  in  the  study,  signiﬁcant  results  were  obtained  and
hese  can  be  used  to  consider  the  risk  of  GS  upgrade  in
atients  with  GS  3  +  3.
onclusionse  conclude  that  it  is  important  to  use  as  many  tools  as  pos-
ible  to  make  accurate  decisions  and  to  identify  the  patients
t  high  risk  of  pathologic  upgrading  that  might  beneﬁt  fromR.  Ugalde-Resano  et  al.
ore  meticulous  evaluation  and/or  aggressive  treatment.
SAD  should  be  routinely  used  to  identify  patients  with
pparently  low-risk  cancer  at  risk  of  GS  upgrade,  resulting
n  a more  accurate  selection  of  candidates  for  AS.  According
o  our  data,  we  can  avoid  a  potentially  incorrect  GS  staging
n  approximately  43%  of  the  cases.
We  found  a  high  frequency  of  GS  upgrade  in  our  popula-
ion.  In  our  study,  PSAD  values  were  signiﬁcantly  associated
ith  upgrading  and  the  most  accurate  cut-off  value  was
.17  ng/ml2. We  recommend  that  a  local  review  of  GS
pgrade  risk  and  its  potential  predictors  be  carried  out  at
ll  hospital  centers  before  offering  active  surveillance  to
otential  candidates.
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